Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 17/20 | 0.75 |
| ▸ | MEN1 | O00255 | 1/20 | 0.75 |
| ▸ | MLNR | O43193 | 1/20 | 0.75 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.75 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.75 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.75 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.75 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.75 |
| ▸ | HTT | P42858 | 1/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.75 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.75 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.75 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22747106 | 0.92 | CACNA1B (0.67) | CACNA1BMEN1MLNRNR1I2CACNA1H | |
| SCHEMBL20130668 | 0.91 | CACNA1B (0.83) | CACNA1BMEN1MLNRNR1I2CACNA1H | |
| SCHEMBL27014864 | 0.90 | CACNA1B (0.67) | CACNA1BMEN1MLNRNR1I2CACNA1H | |
| SCHEMBL22747107 | 0.89 | CACNA1B (0.71) | CACNA1BMEN1MLNRNR1I2CACNA1H | |
| SCHEMBL21504535 | 0.89 | CACNA1B (0.73) | CACNA1BMEN1MLNRNR1I2CACNA1H | |
| SCHEMBL13954156 | 0.88 | CACNA1B (0.72) | CACNA1BMEN1MLNRNR1I2CACNA1H | |
| Cilnidipine SCHEMBL31398437 | 0.86 | CACNA1C (1.00) | CACNA1BMEN1MLNRNR1I2CACNA1H | |
| Cilnidipine SCHEMBL29367885 | 0.86 | CACNA1C (1.00) | CACNA1BMEN1MLNRNR1I2CACNA1H | |
| Cilnidipine SCHEMBL25550 | 0.86 | CACNA1C (1.00) | CACNA1BMEN1MLNRNR1I2CACNA1H | |
| Cilnidipine SCHEMBL30209784 | 0.86 | CACNA1C (1.00) | CACNA1BMEN1MLNRNR1I2CACNA1H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240016787-A1 | METHODS FOR TREATMENT OF CANCER AND PHAGOCYTOSIS-DEFICIENCY RELATED DISEASES | Rdiscovery, LLC (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240016787-A1 | METHODS FOR TREATMENT OF CANCER AND PHAGOCYTOSIS-DEFICIENCY RELATED DISEASES | Rdiscovery, LLC (US) | 2024-01-18 | — | — | US | disclosed |
| US-20220169613-A1 | Drp1-FILAMIN COMPLEX FORMATION INHIBITORS | Rdiscovery, LLC | 2022-06-02 | — | — | US | disclosed |
| WO-2022098642-A1 | THERAPIES FOR TREATMENT OF CANCER AND PHAGOCYTOSIS-DEFICIENCY RELATED DISEASES | Rdiscovery, LLC (US) | 2022-05-12 | — | — | WO | disclosed |
| WO-2020241638-A1 | Drp1-FILAMIN COMPLEX FORMATION INHIBITORS | KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) | 2020-12-03 | — | — | WO | disclosed |
| WO-2005042486-A1 | 1,4-DIHYDROPYRIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE | MYOGEN, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169613-A1 | Drp1-FILAMIN COMPLEX FORMATION INHIBITORS | FIS1, DNM1L, DNM1 | CACNA1B 494/4885MEN1 3581/4885MLNR 3592/4885 |
| US-20240016787-A1 | METHODS FOR TREATMENT OF CANCER AND PHAGOCYTOSIS-DEFICIENCY RELATED DISEASES | MFN2, DNM1L, DNM1 | CACNA1B 3651/4885MEN1 1605/4885MLNR 2907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.